W Polsce: Wkrótce rekrutacjaNa świecie: RekrutujeFaza III
A Randomized, Open-label, Phase 3 Study of Rina-S ± Bevacizumab Versus Investigator's Choice of Platinum-Based Chemotherapy ± Bevacizumab as 2L Treatment in Participants With…
Miasta: Białystok, Gdańsk, Gdynia, Poznań i 2 inne miastaWiek: od 18 latSponsor: Genmab A/S
RekrutujeFaza III
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
Miasta: Gdańsk, Kraków, Warszawa, WrocławWiek: od 18 latSponsor: Incyte Corp.
RekrutujeFaza III
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Miasta: Katowice, Kraków, WarszawaWiek: od 18 latSponsor: Revolution Medicines Inc.
RekrutujeFaza III
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
Miasta: Koszalin, Kraków, Olsztyn, Warszawa i 1 inne miastoWiek: od 18 latSponsor: AstraZeneca AB
RekrutujeFaza III
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Miasta: Chorzów, Gdańsk, Gliwice, Katowice i 8 innych miastWiek: od 18 latSponsor: BioNTech SE
W Polsce: Rekrutacja zakończonaNa świecie: RekrutujeFaza II/III
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast…
Miasta: Biała Podlaska, Opole, Skórzewo, Warszawa i 1 inne miastoWiek: od 18 latSponsor: Bristol-Myers Squibb Services Unlimited Company
RekrutujeFaza III
A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC
Miasta: Kielce, Lublin, Olsztyn, Otwock i 6 innych miastWiek: od 18 latSponsor: Maia Biotechnology Inc.
RekrutujeFaza III
A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigator’s Choice of Chemotherapy (Paclitaxel…
Miasta: Gdańsk, Kraków, Warszawa, ŁódźWiek: od 18 latSponsor: AstraZeneca AB
RekrutujeFaza III
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle…
Miasta: Bydgoszcz, Poznań, WarszawaWiek: od 18 latSponsor: Ferring Pharmaceuticals
RekrutujeFaza III
A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype
Miasta: Gdańsk, Kraków, WarszawaWiek: od 18 latSponsor: Secura Bio Limited
RekrutujeFaza III
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With…
Miasta: Biała Podlaska, Białystok, Kraków, Poznań i 1 inne miastoWiek: od 18 latSponsor: Jazz Pharmaceuticals Ireland Limited
RekrutujeFaza III
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
Miasta: Białystok, Bydgoszcz, Lublin, Peremyshl i 6 innych miastWiek: od 18 latSponsor: Janssen Cilag International
RekrutujeFaza I/II
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
Miasta: Kraków, WarszawaWiek: od 18 latSponsor: AstraZeneca AB
RekrutujeFaza III
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive…
Miasta: Białystok, Bydgoszcz, Gdańsk, Gdynia i 8 innych miastWiek: od 18 latSponsor: AstraZeneca
W Polsce: Rekrutacja zakończonaNa świecie: RekrutujeFaza II/III
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Miasta: Gdynia, Katowice, Kraków, Lublin i 4 inne miastaWiek: od 18 latSponsor: Merck Sharp & Dohme LLC